Australia's Chimeric Therapeutics rises on deal with Be The Match BioTherapies

Chimeric Therapeutics

04/03/2022 03:28

** Shares of Chimeric Therapeutics  CHM.AX  rise as much as
3.2% to A$0.160 - set for best week since July 30, 2021, if
gains hold
    ** Biotech co enters https://www.asx.com.au/asxpdf/20220304/pdf/456q1cb8m1zhqf.pdf
 a strategic partnership with cell and gene therapy solutions
provider Be The Match BioTherapies
    ** Says partnership will leverage Be The Match BioTherapies'
optimised solutions to accelerate development timelines and
expand trial access for co's CHM 1101 (CLTX CAR T) programme
    ** Adds Chlorotoxin CAR T (CLTX CAR T) cell therapy has the
potential to address unmet medical needs of patients with
recurrent/progressive glioblastoma, a type of tumour 
    ** Stock down ~38.2% this year, as of last close 

 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))